Home 'Suicidal ideation' leads to end of Amgen-AstraZeneca drug partnership
 

Keywords :   


'Suicidal ideation' leads to end of Amgen-AstraZeneca drug partnership

2015-05-26 23:58:21| Biotech - Topix.net

Amgen has pulled out of a co-development deal it had with AstraZeneca for an experimental psoriasis drug, which was in the late stages of clinical development, after observing "suicidal ideation" in some patients during clinical testing of the new drug candidate. Dr. Sean E. Harper , executive vice president of research and development at Amgen, said the company believed the likelihood of the drug being required to carry warning labels of suicide risk would limit the potential market for the treatment.

Tags: end drug leads partnership

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
23.11 SP 4
23.1122SSS64UL-S
23.11
23.11725 TYPE H
23.11 3
23.11 Studiologic NumaCompact2
23.11Switch EL Pro
23.11 22
More »